TABLE 1.
Cefiderocol susceptibility interpretative criteria, as of February 2021a
| Organism | CLSI |
FDA |
EUCAST |
USCAST |
||||
|---|---|---|---|---|---|---|---|---|
| MIC (mg/liter) | Zone diam (mm) | MIC (mg/liter) | Zone diam (mm) | MIC (mg/liter) | Zone diam (mm) | MIC (mg/liter) | Zone diam (mm) | |
| Enterobacterales spp. | ||||||||
| Pneumonia | ≤4 | ≥16 | ≤4 | ≥16 | ≤2 | ≥22 | ≤2 | − |
| Nonpneumonia | ≤4 | ≥16 | ≤4 | ≥16 | ≤2 | ≥22 | ≤4 | − |
| P. aeruginosa | ||||||||
| Pneumonia | ≤4 | ≥18 | ≤1 | ≥22 | ≤ 2 | ≥22 | ≤2 | − |
| Nonpneumonia | ≤4 | ≥18 | ≤1 | ≥22 | ≤ 2 | ≥22 | ≤4 | − |
| Acinetobacter spp. | ≤4 | ≥15 | ≤1 | ≥19 | IE | − | IE | − |
| S. maltophilia | ||||||||
| Pneumonia | ≤1 | ≥15 | − | – | IE | − | IE, ≤2 | − |
| Nonpneumonia | ≤1 | ≥15 | − | – | IE | − | IE, ≤4 | − |
a
CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FDA, Food and Drug Administration; USCAST, U.S. Committee on Antimicrobial Susceptibility Testing; –, no breakpoint listed; IE, clinical efficacy data are limited, but in vitro and pharmacokinetic/pharmacodynamic activity support use in difficult-to-treat cases.